1. Japan Stocks

  2. •

    Process industries

  3. •

    Agricultural commodities/Milling
Mitsui DM Sugar Co.Ltd.

Mitsui DM Sugar Co.Ltd.

TTSE:2109
3,755.00
JPY
+15.00
(+0.40%)
105.80BMarket Cap
Oct 30Next Earn
Mitsui DM Sugar Co.Ltd.
TSE:2109
(Tokyo Stock Exchange)

Recent

price

3,755.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
3,004.04
2,993.68
3,607.5
3,633.08
3,602.48
3,796.1
3,863.71
3,943.05
3,942.51
4,383.46
4,236.61
4,566.81
5,060.59
5,292.48
5,539.92
5,761.9
- -
Revenue per Share
150.13
95.33
166.89
197.31
213.91
283.87
280.18
311.31
256.98
93.25
107.54
112.93
245.14
261.72
195.06
126.72
- -
Basic EPS, GAAP
109.75
-70.98
111.58
275.56
94.12
111.36
223.64
393.37
145.98
159.47
203.61
-124.79
-363.45
159.39
574.27
195.6
- -
Free Cash Flow per Basic Share
49.91
35
34.91
34.91
44.94
59.8
74.74
114.71
114.71
81.08
49.92
49.78
60.18
150.49
135.41
132.22
- -
Dividend per Share
1,909.39
1,847.39
2,112.87
2,301.33
2,459.12
2,657.13
2,872.85
3,083.46
3,200.94
3,218.68
3,315.45
3,136.21
3,305.35
3,475.64
3,550.63
3,599.58
3,599.58
Book Value per Share
1,907.34
1,830.91
2,083.62
2,276.02
2,344.62
2,526.04
2,774.96
3,012.34
2,876.25
2,920.77
3,063.95
2,939.1
3,011.89
3,201
3,288.55
3,509.92
3,509.92
Tangible Book Value per Share
27
27
27
27
27
27
27
27
27
26
26
32
32
32
32
31
32
Basic Weighted Avg Shares
80,720
80,049
96,213
96,891
96,114
101,379
103,177
105,291
105,274
113,854
108,887
147,880
163,310
170,774
178,785
180,102
- -
Sales/Revenue/Turnover
7.81
5.63
4.27
5.39
4.02
5.42
5.06
6.04
3.56
4.26
3.34
2.46
0.67
2.49
7.74
7.17
- -
Operating Margin (%)
2,199
2,207
3,633
3,408
3,797
4,426
4,849
4,954
5,076
5,937
6,181
6,373
6,580
6,779
6,527
6,406
- -
Depreciation Expense
4,034
2,549
4,451
5,262
5,707
7,581
7,482
8,313
6,862
2,422
2,764
3,657
7,911
8,445
6,295
3,961
- -
Net Income, GAAP
38.95
37.37
35.97
37.88
36.04
35.06
34.79
33.6
30
44.4
44.18
36.32
49.89
23.78
42.3
67.64
- -
Effective Tax Rate (%)
5
3.18
4.63
5.43
5.94
7.48
7.25
7.9
6.52
2.13
2.54
2.47
4.84
4.95
3.52
2.2
- -
Profit Margin (%)
9,235
10,009
15,653
18,078
25,434
28,451
32,518
36,821
18,422
30,646
33,150
46,467
50,672
55,342
52,933
44,976
44,976
Working Capital
1,206
2,785
4,527
3,973
13,261
13,423
13,121
12,509
2,901
11,583
10,889
14,974
36,554
36,219
28,343
17,803
17,803
LT Debt
52,131
53,196
60,483
65,721
71,581
77,398
83,680
89,869
95,060
92,396
91,678
109,924
112,574
117,338
119,339
114,594
114,594
Total Equity
7.04
4.88
3.87
4.1
2.81
3.66
3.32
3.95
2.33
2.34
1.77
1.8
0.36
2
4.75
2.55
- -
Return on Invested Capital (%)
7.55
4.47
6.7
6.67
6.45
7.57
6.92
7.42
5.84
2.03
2.37
3.01
5.98
5.6
4.3
3.56
- -
Return on Capital (%)
8.06
4.92
8.19
8.94
8.98
11.1
10.13
10.45
8.18
2.88
3.29
3.92
7.59
7.7
5.55
3.5
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
14,944
19,757
LT Borrowings
- -
26,819
17,168
LT Finance Leases
- -
753
635
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
95,180
99,574
105,797

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
94,922
86,058
Cash, Cash Equivalents & STI
- -
41,990
29,508
Accounts Receivable, Net
- -
13,718
12,671
Inventories
- -
33,607
40,315
Total Current Liabilities
- -
42,593
41,082
Payables & Accruals
- -
- -
- -
ST Debt
- -
14,944
19,757
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.2%
4.85%
-3.98%
Free Cash Flow
20.89%
12.5%
-67.01%
Net Income, GAAP
3.46%
18.57%
-37.08%
Sales/Revenue/Turnover
6.38%
11.25%
0.74%
Total Cash Common Dividend
- -
36.15%
-5.42%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
42,358
41,859
45,181
41,376
170,774
2025
- -
- -
- -
- -
178,785
2026
- -
- -
- -
- -
180,102

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
171.95
16.02
13.51
60.21
261.72
2025
- -
- -
- -
- -
195.06
2026
- -
- -
- -
- -
126.72

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
150.49
2025
- -
- -
- -
- -
135.41
2026
- -
- -
- -
- -
132.22
Similar Companies
Patanjali Foods Limited (NSE:PATANJALI)
Tilray Brands, Inc. (NASDAQ:TLRY)
Archer-Daniels-Midland Company (NYSE:ADM)
Corteva, Inc. (NYSE:CTVA)
Canopy Growth Corporation (NASDAQ:CGC)
Balrampur Chini Mills Ltd (NSE:BALRAMCHIN)
Business
Mitsui DM Sugar Co., Ltd. manufactures and sells refined sugar, sugar-related products, functional foods, and engages in real estate activities in Japan. The company produces raw sugar, refined sugar from sugarcane and sugar beets; rock sugar, liquid sugar, brown crystal sugar, sugar stick sachets, powdered sugar, gum syrup, soft drink concentrates; centrifugal sugar, black sugar; sweeteners, food ingredients, food additives; nutritional care products, dysphagia products; functional foods; and product packaging materials. It also develops and sells products for lifestyle support and home-delivery lunch boxes; leases land and buildings; and operates warehouses. Established on September 4, 1947 and headquartered at Mita S-Garden, 26-16 Shiba 5-chome, Minato-ku, Tokyo, Japan, the company lists its shares on the Tokyo Stock Exchange Prime Market under ticker 2109 and counts Mitsui & Co., Ltd. and Mitsubishi Corporation among its major shareholders. In April 2025, Mitsui DM Sugar merges its holding company structure by absorbing consolidated subsidiary DM Mitsui Sugar Co., Ltd. and changes its name from Mitsui DM Sugar Holdings Co., Ltd. to Mitsui DM Sugar Co., Ltd., streamlining operations while renewing its corporate website. The company reports extraordinary income of 47,341 million yen from a subsidiary merger, excluding impact on consolidated financial results. It plans to launch the Osakana Kakumei brand of plant-based bluefin tuna in 2026 via subsidiary Taisho Technos to address rising seafood costs and production declines, targeting annual output of 10 tonnes by 2028 alongside potential expansions to salmon and squid alternatives. In September 2022, it agrees to acquire Terumo Corporation's enteral formula business.